Sangamo Therapeutics, Inc.

Good morning and welcome to Sangamo Therapeutics' third quarter 2025 conference call. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker today, Louise Wilkie, Head of Investor Relations and Corporate Communications. Please go ahead.

Thank you. Good morning, everyone. Thank you for joining us on the call today. On this call are several members of the Sangamo Executive Leadership Team, including Sandy McRae, Chief Executive Officer, Natalie Dubostring, Fellow Chief Development Officer, Greg Davis, Head of Research and Technology. Prathisha Durrababu, Principal Financial Officer and Principal Accounting Officer. Slides from our corporate presentation can be found on our website, sangamo.com, and under the Presentations page of the Investors and Media section. This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements relating to Sangamo's cash runway, Sangamo's plans to obtain additional capital and its ability to continue to operate as a going concern, the therapeutic and commercial potential and value of Sangamo's product candidates and technologies, Sangamo's ability to establish and maintain collaborations and strategic partnerships, including for its Fabry disease program, the anticipated plans and timelines of Sangamo and its collaborators for clinical trials, clinical data presentations and releases, regulatory submissions and regulatory approvals, upcoming catalysts and milestones, and other statements that are not historical fact. Actual results may differ materially from what we discussed today. These statements are subject to certain risks and uncertainties that are discussed in our filings with the SEC, specifically in our annual report on Form 10-K for the fiscal year ended December 31, 2024, and our quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2025, and subsequent filings and reports that Sangamon makes from time to time with the SEC. The forward-looking statements stated today are made as of today, and we undertake no duty to update such information except as required by law. please note that all forward-looking statements about our future plans and expectations are subject to our ability to secure adequate additional funding. Now, I'll turn the call over to our CEO, Andy McRae.

Thank you, Louise, and good morning to everyone joining the call today. This quarter, we continue to advance our clinical and preclinical pipeline while managing our cash resources carefully. In September, we presented promising detailed clinical data from a registrational star study in Fabry disease, demonstrating the potential for ST920 as a one-time durable treatment of the underlying pathology of Fabry disease for all types of Fabry disease patients. And in October, We were pleased to hold a meeting with the FDA to discuss the proposed efficacy and safety data package for a planned BLA submission where, in the meeting minutes, the FDA reaffirmed its October 2024 agreement to use EGFR slope as an endpoint to support an accelerated approval pathway. A particular highlight for me this quarter was attending the 15th annual Fabry Family Education Conference that brought together more than 200 Fabry patients, family members and volunteers to provide educational presentations and gather insights from patients, including those who have received SC920. This is an event we are privileged to attend each year and it was humbling to spend time with this group of inspirational people of all age groups to learn more about their experiences with Fabry disease. I found it striking to hear firsthand the challenges these patients face, including their experiences with currently available treatments. You also see the hope they have for treatment breakthroughs and their strong understanding of scientific advances and their unwavering support for one another. I came away from the event more convinced than ever that patients are seeking an alternative to current standards of care alongside the peaks and troughs and associated symptoms that they can bring. Gene therapy, where the alpha-galli enzyme is expressed all day, every day by the liver, is a fundamentally different treatment modality to what is available today. I was lucky to meet with some patients who received SC920 as part of the STAR study, and their enthusiasm and excitement was overwhelming. They couldn't wait to tell me their experiences, and one patient approached me to share how SC920 has completely transformed their life. We have a responsibility to bring this medicine to the Fabry community. In our prioritized neurology pipeline, we are excited now to be recruiting and enrolling patients in the Phase 1-2 STAND study in chronic neuropathic pain, our first-ever neurology clinical study, following the activation of the first two clinical sites. We also continue to advance our PRIAM program ahead of the planned CTA submission next year. I would like to now hand directly over to Nathalie Dubois-Stringfellow, our Chief Development Officer, to provide additional details on these important programmes. Prathusha Durrababu, our Principal Financial Officer, and I will then close the call by summarising the key business and financial takeaways from this quarter. Nathalie.